fludarabine IV

P1, N=31, Completed, Fate Therapeutics | Active, not recruiting --> Completed

P1, N=54, Active, not recruiting, Fate Therapeutics | Trial primary completion date: Sep 2024 --> Jun 2025

P1/2, N=28, Recruiting, Cabaletta Bio | N=12 --> 28 | Trial completion date: Dec 2027 --> Dec 2029 | Trial primary completion date: Dec 2027 --> Dec 2029

P1, N=18, Not yet recruiting, Juventas Cell Therapy Ltd.

P1, N=36, Recruiting, Nanjing Legend Biotech Co. | Not yet recruiting --> Recruiting

P1, N=51, Active, not recruiting, Artiva Biotherapeutics, Inc. | Recruiting --> Active, not recruiting

We propose that such a low-intensity regimen may be suitable for older patients with AML, who are unfit for intensive chemotherapy. We also present data indicating that PRI5202 induces myeloid differentiation in blasts from patients with myelodysplastic syndrome (MDS), and we propose to further investigate PRI5202 as a differentiation therapy for patients suffering from MDS.

However, to our best knowledge, there has been no report about modification of fludarabine (Flu)/melphalan (Mel)-based PTCy-haplo in a real-world setting...In addition, despite the poor baseline characteristics including older age (median, 59 years [range, 25-72]), active diseases at the time of PTCy-haplo (n=8), and short interval between the first and second allogeneic hematopoietic stem cell transplantation (allo-HSCT) (n=8; median, 12.4 months [range, 3.9-32.9]; all patients received Flu/busulfan (Bu)-based conditioning regimen for their first allo-HSCT), only two patients (10.5%) developed sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD). With a median follow-up of 30.2 months (range, 1.0-53.1), overall survival and disease-free at 2 years were 56.8 and 51.5%, respectively. These findings suggested that early TAC initiation using Flu/Mel-based PTCy-haplo may be potentially useful for older patients with low tolerance to CRS, high risk of SOS/VOD or recurrence, or for those who are unlikely to receive Bu-based conditioning regimen due to early relapse after allo-HSCT with Bu-based conditioning regimen.

P2, N=70, Suspended, St. Jude Children's Research Hospital | Recruiting --> Suspended

Universal BE-CAR7 T cells induced leukemic remission in patients with relapsed or refractory T-cell ALL, thus allowing successful allogeneic hematopoietic stem-cell transplantation in most of the patients. (Funded by the Medical Research Council and others; ISRCTN Registry number, ISRCTN15323014.).

P1, N=43, Active, not recruiting, UNC Lineberger Comprehensive Cancer Center | Recruiting --> Active, not recruiting | Trial completion date: Sep 2041 --> Nov 2039 | Trial primary completion date: Sep 2026 --> Dec 2025

P1, N=15, Not yet recruiting, Juventas Cell Therapy Ltd.